By expressing inhibitory receptors such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) (which binds to CD80/86 derived from cancer cells) and PD-1, Tregs disrupt costimulatory signaling and suppress antitumor T-cell activity. The gene discussed is CTLA4; the disease is cancer.